<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>exclude-sidebar &#8211; BJC TV</title>
	<atom:link href="https://tv.bjcardio.co.uk/tag/exclude-sidebar/feed/" rel="self" type="application/rss+xml" />
	<link>https://tv.bjcardio.co.uk</link>
	<description>Short video updates for cardiologists</description>
	<lastBuildDate>Wed, 23 Sep 2026 12:40:52 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://tv.bjcardio.co.uk/wp-content/uploads/2023/06/cropped-favicon-32x32.png</url>
	<title>exclude-sidebar &#8211; BJC TV</title>
	<link>https://tv.bjcardio.co.uk</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>&#8220;Treatment Limbo&#8221; – what is it and how can we avoid it?</title>
		<link>https://tv.bjcardio.co.uk/lipids-2/treatment-limbo-what-is-it-and-how-can-we-avoid-it/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Wed, 19 Aug 2026 11:15:00 +0000</pubDate>
				<category><![CDATA[Lipids]]></category>
		<category><![CDATA[exclude-sidebar]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Sponsored Video 2026]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=10417</guid>

					<description><![CDATA[Dr Adie Viljoen and Dr Mohamed Elnaggar address the challenge of “Treatment Limbo”, in dyslipidaemia management, where patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets yet remain ineligible for advanced therapies. They introduce a guideline-aligned, alternative approach that tailors treatment to baseline LDL-C and distance to goal, supporting timely intervention and helping to reduce the risk of recurrent cardiovascular events.]]></description>
										<content:encoded><![CDATA[
<h5 class="wp-block-heading">Further resource</h5>



<p class="wp-block-paragraph"><a href="https://resources.bjcardio.co.uk/staying-on-track-on-demand/" rel="nofollow noopener" target="_blank">Watch a full-length on-demand video and explore other educational materials, designed to further your understanding of avoiding treatment limbo and alternative approaches to managing dyslipidaemia</a>.</p>



<p class="wp-block-paragraph"><a href="https://pro.campus.sanofi/dam/jcr:55f30477-c7e2-49c0-8cfc-16966f28d4c2/" rel="nofollow noopener" target="_blank">Click here</a> to access prescribing information and adverse event reporting information for Praluent® (alirocumab).</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
